心律平为一广谱有效抗心律失常药。一般认为其副作用少,但各家报道不一,从4%～46.9%不等,患者一般多能耐受,经1～3周恢复正常。但心律平有致心律失常危险,国内已有引起室颤报道。用心律平出现传导障碍者占17.3%,以Ⅰ°A-VB最为常见。本文报道1例首剂心律平致Ⅲ°A-VB以引起临床医师重视。患者女,62岁,以冠心病劳累性心绞痛诊断入院。 Cardiac rhythm is a broad-spectrum antiarrhythmic drug. Generally considered less side effects, but various reports vary from 4% to 46.9%, patients generally tolerate more, after 1 to 3 weeks to return to normal. However, there is a risk of heart arrhythmia arrhythmia, ventricular fibrillation has been reported in China. 17.3% of patients with conduction impairment appear in the heart rhythm, with Ⅰ ° A-VB being the most common. This article reports 1 case of first dose of cardiac arrhythmia Ⅲ ° A-VB to attract clinicians attention. Female, 62 years old, diagnosed with coronary heart disease with exertional angina.